Cargando…

In vivo selection of the MDA-MB-231br/eGFP cancer cell line to obtain a clinically relevant rat model for triple negative breast cancer brain metastasis

Young triple negative breast cancer (TNBC) patients are at high risk for developing very aggressive brain metastases associated with a poor prognosis and a high mortality rate. Preclinical models that allow follow-up by magnetic resonance imaging (MRI) can contribute to the development of new therap...

Descripción completa

Detalles Bibliográficos
Autores principales: De Meulenaere, Valerie, Descamps, Benedicte, De Wever, Olivier, Vanhove, Christian, Deblaere, Karel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710086/
https://www.ncbi.nlm.nih.gov/pubmed/33264355
http://dx.doi.org/10.1371/journal.pone.0243156
_version_ 1783617876246134784
author De Meulenaere, Valerie
Descamps, Benedicte
De Wever, Olivier
Vanhove, Christian
Deblaere, Karel
author_facet De Meulenaere, Valerie
Descamps, Benedicte
De Wever, Olivier
Vanhove, Christian
Deblaere, Karel
author_sort De Meulenaere, Valerie
collection PubMed
description Young triple negative breast cancer (TNBC) patients are at high risk for developing very aggressive brain metastases associated with a poor prognosis and a high mortality rate. Preclinical models that allow follow-up by magnetic resonance imaging (MRI) can contribute to the development of new therapeutic approaches for brain metastasis. To date, preclinical brain tumor research has almost exclusively relied on xenograft mouse models. Yet, rats are an ideal model for imaging of brain metastasis as their larger brain offers better relative spatial resolution compared to a mouse brain. For the development of a clinically relevant rat model for TNBC brain metastasis, the MDA-MB-231br/eGFP cancer cell line can be used. However, as a result of species-dependent extracranial features, the propensity of the MDA-MB-231br/eGFP cancer cell line to metastasize exclusively to the brain needs to be enhanced by in vivo selection. In this study, repeated sequential passages of metastatic cancer cells obtained from brain metastases in nude rats were performed. Brain metastasis formation was evaluated using preclinical MRI, while bone metastasis formation was assessed using high-resolution computed tomography (CT) and 2-deoxy-2-[(18)F] fluoro-D-glucose ([(18)F] FDG) positron emission tomography (PET) imaging. Our results demonstrated that the metastatic tumor burden in the rat brain (number and volume) significantly increased with increasing passage, while the metastatic tumor burden in the skeleton (i.e., number of metastasis-affected bones) significantly decreased with increasing passage. However, bone metastasis development was not reduced to a negligible amount. Consequently, despite in vivo selection, our rat model is not recommended for investigating brain metastasis as a single disease. Our findings highlight the importance of well-reasoned selection of both the preclinical model and the cancer cell line in order to obtain reliable and reproducible scientific results.
format Online
Article
Text
id pubmed-7710086
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-77100862020-12-03 In vivo selection of the MDA-MB-231br/eGFP cancer cell line to obtain a clinically relevant rat model for triple negative breast cancer brain metastasis De Meulenaere, Valerie Descamps, Benedicte De Wever, Olivier Vanhove, Christian Deblaere, Karel PLoS One Research Article Young triple negative breast cancer (TNBC) patients are at high risk for developing very aggressive brain metastases associated with a poor prognosis and a high mortality rate. Preclinical models that allow follow-up by magnetic resonance imaging (MRI) can contribute to the development of new therapeutic approaches for brain metastasis. To date, preclinical brain tumor research has almost exclusively relied on xenograft mouse models. Yet, rats are an ideal model for imaging of brain metastasis as their larger brain offers better relative spatial resolution compared to a mouse brain. For the development of a clinically relevant rat model for TNBC brain metastasis, the MDA-MB-231br/eGFP cancer cell line can be used. However, as a result of species-dependent extracranial features, the propensity of the MDA-MB-231br/eGFP cancer cell line to metastasize exclusively to the brain needs to be enhanced by in vivo selection. In this study, repeated sequential passages of metastatic cancer cells obtained from brain metastases in nude rats were performed. Brain metastasis formation was evaluated using preclinical MRI, while bone metastasis formation was assessed using high-resolution computed tomography (CT) and 2-deoxy-2-[(18)F] fluoro-D-glucose ([(18)F] FDG) positron emission tomography (PET) imaging. Our results demonstrated that the metastatic tumor burden in the rat brain (number and volume) significantly increased with increasing passage, while the metastatic tumor burden in the skeleton (i.e., number of metastasis-affected bones) significantly decreased with increasing passage. However, bone metastasis development was not reduced to a negligible amount. Consequently, despite in vivo selection, our rat model is not recommended for investigating brain metastasis as a single disease. Our findings highlight the importance of well-reasoned selection of both the preclinical model and the cancer cell line in order to obtain reliable and reproducible scientific results. Public Library of Science 2020-12-02 /pmc/articles/PMC7710086/ /pubmed/33264355 http://dx.doi.org/10.1371/journal.pone.0243156 Text en © 2020 De Meulenaere et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
De Meulenaere, Valerie
Descamps, Benedicte
De Wever, Olivier
Vanhove, Christian
Deblaere, Karel
In vivo selection of the MDA-MB-231br/eGFP cancer cell line to obtain a clinically relevant rat model for triple negative breast cancer brain metastasis
title In vivo selection of the MDA-MB-231br/eGFP cancer cell line to obtain a clinically relevant rat model for triple negative breast cancer brain metastasis
title_full In vivo selection of the MDA-MB-231br/eGFP cancer cell line to obtain a clinically relevant rat model for triple negative breast cancer brain metastasis
title_fullStr In vivo selection of the MDA-MB-231br/eGFP cancer cell line to obtain a clinically relevant rat model for triple negative breast cancer brain metastasis
title_full_unstemmed In vivo selection of the MDA-MB-231br/eGFP cancer cell line to obtain a clinically relevant rat model for triple negative breast cancer brain metastasis
title_short In vivo selection of the MDA-MB-231br/eGFP cancer cell line to obtain a clinically relevant rat model for triple negative breast cancer brain metastasis
title_sort in vivo selection of the mda-mb-231br/egfp cancer cell line to obtain a clinically relevant rat model for triple negative breast cancer brain metastasis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710086/
https://www.ncbi.nlm.nih.gov/pubmed/33264355
http://dx.doi.org/10.1371/journal.pone.0243156
work_keys_str_mv AT demeulenaerevalerie invivoselectionofthemdamb231bregfpcancercelllinetoobtainaclinicallyrelevantratmodelfortriplenegativebreastcancerbrainmetastasis
AT descampsbenedicte invivoselectionofthemdamb231bregfpcancercelllinetoobtainaclinicallyrelevantratmodelfortriplenegativebreastcancerbrainmetastasis
AT deweverolivier invivoselectionofthemdamb231bregfpcancercelllinetoobtainaclinicallyrelevantratmodelfortriplenegativebreastcancerbrainmetastasis
AT vanhovechristian invivoselectionofthemdamb231bregfpcancercelllinetoobtainaclinicallyrelevantratmodelfortriplenegativebreastcancerbrainmetastasis
AT deblaerekarel invivoselectionofthemdamb231bregfpcancercelllinetoobtainaclinicallyrelevantratmodelfortriplenegativebreastcancerbrainmetastasis